Bright Minds Biosciences (DRUG)
NASDAQ:DRUG
Want to see DRUG full AI Analyst Report?
Top Page
Bright Minds Biosciences
(NASDAQ:DRUG)
Select Model
Select Model
Rating:44Neutral
Price Target:
$58.00
▼(-35.48% Downside)
Action:N/A
Date:06/17/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and increasing cash burn) despite a relatively strong, low-debt balance sheet. Technicals add further downside pressure given the pronounced downtrend, while valuation provides limited support because negative earnings and no dividend make standard valuation signals less informative.
Positive Factors
Conservative balance sheet, minimal debt
A very low debt load combined with a materially larger equity base reduces financial distress risk and preserves strategic optionality. Over the next 2–6 months this capital structure supports continued R&D spending, potential partnering flexibility, and lowers default risk versus leveraged peers.
Negative Factors
No revenue and widening net losses
Persisting zero revenue alongside materially larger losses underscores that current operations are entirely pre-revenue. That structural loss profile increases dependence on external capital and heightens execution risk: absent clear clinical readouts, financial deficits can force dilution or program prioritization decisions.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet, minimal debt
A very low debt load combined with a materially larger equity base reduces financial distress risk and preserves strategic optionality. Over the next 2–6 months this capital structure supports continued R&D spending, potential partnering flexibility, and lowers default risk versus leveraged peers.
Read all positive factors
Bright Minds Biosciences (DRUG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$585.47M
Dividend YieldN/A
Average Volume (3M)102.09K
Price to Earnings (P/E)―
Beta (1Y)5.32
Revenue GrowthN/A
EPS Growth-552.93%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.39
Shares Outstanding9,787,161
10 Day Avg. Volume115,326
30 Day Avg. Volume102,086
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.07
Price to Sales (P/S)0.00
P/FCF Ratio-66.78
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.60K
Enterprise Value/Ebitda-11.15
Forecast
1Y Price Target
$164.25Price Target Upside82.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.67
Revenue Forecast (FY)N/A
Bright Minds Biosciences Business Overview & Revenue Model
Company Description
Bright Minds Biosciences Inc. is a preclinical biotechnology firm dedicated to creating serotonin-based therapies. Its primary goal is to enhance the well-being of individuals suffering from severe and life-altering conditions. The company's devel...
How the Company Makes Money
Bright Minds Biosciences does not appear to have a mature, recurring commercial product revenue base because it is a clinical-stage drug developer. As a result, its ability to generate revenue and fund operations is typically driven by (a) capital...
Bright Minds Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Sep 2025 | Dec 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -52.93K | -76.87K | -73.36K | -72.45K | -6.04K | 0.00 |
| EBITDA | -31.32M | -13.86M | -2.72M | -7.28M | -14.73M | -8.79M |
| Net Income | -27.50M | -12.23M | -2.80M | -7.37M | -15.19M | -8.52M |
Balance Sheet | ||||||
| Total Assets | 311.34M | 84.42M | 6.10M | 6.88M | 12.09M | 20.04M |
| Cash, Cash Equivalents and Short-Term Investments | 308.68M | 82.91M | 5.72M | 6.75M | 11.63M | 19.76M |
| Total Debt | 81.86K | 125.78K | 118.96K | 73.55K | 139.91K | 0.00 |
| Total Liabilities | 3.82M | 2.38M | 568.26K | 280.86K | 1.54M | 638.57K |
| Stockholders Equity | 307.52M | 82.04M | 5.54M | 6.60M | 10.54M | 19.40M |
Cash Flow | ||||||
| Free Cash Flow | -20.06M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
| Operating Cash Flow | -20.06M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 278.59M | 85.57M | 810.57K | 2.19M | 5.20M | 26.06M |
Bright Minds Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
DRUG
Bright Minds Biosciences
60.66
33.35
122.12%
TSE:NGEN
NervGen Pharma
―
―
―
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.01
-50.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.47
-3.53
-88.25%
Bright Minds Biosciences Corporate Events
Bright Minds Biosciences Sets March 31, 2026 AGM, Files Meeting Materials on Form 6-K
Jun 3, 2026
Bright Minds Biosciences has called its annual general meeting of shareholders for March 31, 2026, in Vancouver, where investors will receive the audited financial statements and MDA for the year ended September 30, 2025. Shareholders will also vo...
Bright Minds Biosciences Sets March 31, 2026 Date for Annual General Meeting
Jun 2, 2026
Bright Minds Biosciences has filed a Form 6-K in the United States on June 2, 2026, to notify investors of its upcoming Annual General Meeting of security holders. The filing underscores the company’s compliance with U.S. and Canadian disclo...
Bright Minds Biosciences to Present at Jefferies Healthcare Conference and Grants New Stock Options
May 28, 2026
On May 26, 2026, Bright Minds Biosciences said it will present at the Jefferies Global Healthcare Conference in New York, underscoring its efforts to raise visibility with investors around its CNS-focused drug pipeline. The company plans a webcast...
Bright Minds Biosciences Boosts Cash Reserves as R&D Losses Widen in Q2 2026 Filing
May 20, 2026
Bright Minds Biosciences filed a Form 6-K on May 19, 2026, furnishing investors with condensed interim consolidated financial statements and management’s discussion and analysis for the six months ended March 31, 2026. The filing shows a sha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.